key: cord-0855227-diembch2
authors: Casale, Maddalena; Baldini, Marina Itala; Del Monte, Patrizia; Gigante, Antonia; Grandone, Anna; Origa, Raffaella; Poggi, Maurizio; Gadda, Franco; Lai, Rosalba; Marchetti, Monia; Forni, Gian Luca
title: Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies
date: 2022-03-25
journal: J Clin Med
DOI: 10.3390/jcm11071826
sha: 347903d069461c586d7573c635665e0f525ca45e
doc_id: 855227
cord_uid: diembch2

Background: The treatment of endocrinopathies in haemoglobinopathies is a continually expanding research area; therefore, recommendations supporting the appropriateness of treatments are a pressing need for the medical community. Methods: The Management Committee of SITE selected and gathered a multidisciplinary and multi-professional team, including experts in haemoglobinopathies and experts in endocrinopathies, who have been flanked by experts with methodological and organizational expertise, in order to formulate recommendations based on the available scientific evidence integrated by personal clinical experience. The project followed the systematic approach for the production of clinical practice guidelines according to the methodology suggested by the National Center for Clinical Excellence, Quality and Safety of Care (CNEC). Results: Out of 14 topics, 100 clinical questions were addressed, and 206 recommendations were elaborated on. The strength of recommendations, panel agreement, a short general description of the topic, and the interpretation of evidence were reported. Conclusions: Good Practice Recommendations are the final outcome of translational research and allow one to transfer to the daily clinical practice of endocrine complications in haemoglobinopathies.

In spite of the outstanding advances in the care of cardiovascular and hepatic complications due to blood transfusions, the management of endocrine complications has been left behind and, nowadays, they are the most frequent and the most resourcedraining complications in haemoglobinopathies [1] . The Italian Society of Thalassemia and Haemoglobinopathies (SITE) has therefore undertaken a project aimed at integrating available evidence with experts' opinions through a systematic method, in order to reach an adequate degree of consensus on the recommendations for the clinical practice. The evidence-based approach adopted for producing Good Practice Recommendations (GPR) allows for a rapid update of the recommendations whenever new evidence becomes available.

This type of indication is fundamental, especially if there is insufficient evidence to provide an evidence-based recommendation, and the panel considers it important to provide a recommendation.

The document is organized in three sections; the list of the clinical questions formulated by the panel and the associated recommendations; a short section dedicated to the definition of endocrinopathy, in order to allow the reader to consider the individual aspects of prevention, diagnosis and treatment, focusing on controversial aspects; and finally, two summary tables, Table 1 , reporting all screening tests to be performed in all patients with haemoglobinopathies and Table 2 , summarizing the diagnostic completion of a subject with abnormal screening tests, in order to give a comprehensive and rapid view on the routine screening and final diagnosis of endocrine disorders. The main part of the document is focused on transfusion-dependent thalassemia, due to the higher frequency of endocrine disorders in this group of patients. Recommendations related to endocrine disorders in non-transfusion-dependent thalassemia and sickle cell disease are reported in a specific chapter at the end of the document. Screening for haemoglobinopathies, determination of the blood group, semen analysis and semen culture are recommended for the partner In pregnant women, test TSH and FT4 every month to the 20th week and another control between the 26th and the 32nd week of pregnancy.

In patients wishing paternity, with failure to conceive after 12 months of unprotected sexual intercourse Semen analysis on an adequately collected sample Every time previous conditions occur

The semen analysis should be repeated if pathologic, one evaluation is enough if normal Bone disorders are not addressed in the present document, as SITE commissioned a specific GPR document on this topic, available on the society website.

The Management Committee of SITE selected and gathered a multidisciplinary and multi-professional team made up of experts in haemoglobinopathies and experts in endocrinopathies, who have been flanked by experts with methodological and organizational expertise, in order to formulate recommendations based on available scientific evidence integrated by experts' opinions, with the purpose of supporting clinicians in the decisionmaking process, and thus improving the appropriateness of treatments.

The members of the scientific panel come from the following areas of competence: 2 clinicians and experts in haemoglobinopathies, and 4 endocrinologists and experts in the management of patients affected by haemoglobinopathies. A urologist and expert in male fertility disorders in haemoglobinopathies and a gynaecologist and expert in female fertility disorders in haemoglobinopathies have also participated in the sections relevant to their expertise.

The project followed a systematic approach, adopting the approach of the Methodological Manual for the production of clinical practice guidelines by the National Center for Clinical Excellence, Quality and Safety of Care (CNEC).

This approach allowed the panel to use already existing guidelines and to contextualize them to the target population, producing recommendations specifically formulated for haemoglobinopathies.

The panel of experts divided the clinical problems into 14 areas of interest; within these areas, specific populations have been identified: males, females, adults, children.

For each area, the scientific panel has identified specific scenarios and formulated the corresponding clinical questions.

The available evidence-based guidelines on the prevention and treatment of endocrinopathies published between 1 January 2010 and 30 June 2021 have been pinpointed, assessed, and selected.

The research was carried out via a systematic review of four main data sources: specific guidelines databases; international health agencies producing guidelines; bibliographic databases with reference only to guidelines; general databases. The keywords used for the literature search are: diabetes mellitus, endocrine system diseases, growth disorders, hypogonadism, hypoparathyroidism, iron overload, complications of beta-thalassemia, beta-thalassemia, sickle cell disease, stature growth disorder, disorder of pubertal development, female infertility, male infertility, pregnancy, glucose metabolism disorder, adrenal insufficiency, GH deficiency in the adult.

The research has been completed with a manual method and asking panel experts about possible "missing papers".

The critical evaluation of the guidelines in terms of quality, novelty, and debated topics was assessed by the panel, who considered it necessary to integrate what had been selected with clinical studies focused on specific evidence for haemoglobinopathies.

The panel, because of the COVID-19 pandemic, which delayed the publication or review of articles, felt they had to keep the publishing window open in order to introduce scientific evidence, if any, into the selected evidence.

A literature search identified a total of 229 titles and abstracts. After a first evaluationcarried out based on abstracts-and a second one-based on full texts-a total of 189 titles and abstracts between Guidelines and reference documents were considered relevant. After completing the assessment of the literature review, the authors answered the formulated questions, specifying the evidence used to support the answer.

The authors presented and discussed what had been prepared during 18, virtual plenary meetings from March 2021 to May 2021.

Following the presentation of the answers, a process took place to reach consensus on the strength and direction of the recommendations.

The GRADE method wad used to allocate the strength degree of the recommendations; recommendations are formulated on two levels: strong and week.

Each recommendation was associated with its strength: Strong recommendation in favour (Green): a strong recommendation is given when there is a high certainty of evidence, proving that the overall benefits of the intervention are clearly greater than the drawbacks.

Strong recommendation against (Red): when there is highly certain evidence showing that the overall drawbacks of the intervention are clearly greater than the benefits. A strong recommendation against is also used when the examination of evidence shows that an intervention is not safe.

Conditioned recommendation in favour (Yellow): when the benefits of the intervention are greater than the drawbacks, but the available evidence cannot definitively determine that negative effects are few or none.

Conditioned recommendation against (Orange): a conditioned recommendation against is given when the drawbacks of the intervention are greater than the benefits, and this is not proven by strong evidence. This recommendation is also used where there is strong evidence of both beneficial and detrimental effects, but the balance between them is difficult to establish. Question no. 5: Which evaluations and examinations are recommended in the case of height growth disorder? Recommendation 5.1 In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: -Pretransfusion Hb; -Phlogosis indicators; -Hepatic and renal function, electrolytes, total proteins, and protein electrophoresis, physical and chemical examination of urine; -Screening for celiac disease (antiTG ± AGA depending on the subject's age, with simultaneous evaluation of IgA); -Thyroid function (FT4, TSH); -Phosphorus-calcium metabolism (calcium, phosphorus, alkaline phosphatase, PTH

Question no. 2 : From what age and how often is screening for a height growth disorder indicated?

Recommendation 2.1 It is recommended to perform screening for a height growth disorder every six months starting from patient intake, until the completion of height growth and pubertal development.

Strength Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 5: Which evaluations and examinations are recommended in the case of height growth disorder? Recommendation 5.1 In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: -Pretransfusion Hb; -Phlogosis indicators; -Hepatic and renal function, electrolytes, total proteins, and protein electrophoresis, physical and chemical examination of urine;

Question no. 2 : From what age and how often is screening for a height growth disorder indicated?

Recommendation 2.1 It is recommended to perform screening for a height growth disorder every six months starting from patient intake, until the completion of height growth and pubertal development.

Strength Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12. 6 In the case of diagnosis of hypogonadotropic hypogonadism, it is recommended to carry out a pituitary MRI to complete the diagnosis.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 13 : In which patients should hormone therapy be started? Recommendation 13.1 In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1. 5 Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12. 6 In the case of diagnosis of hypogonadotropic hypogonadism, it is recommended to carry out a pituitary MRI to complete the diagnosis.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 13 : In which patients should hormone therapy be started? Recommendation 13.1 In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recom-Panel Agreement: Full Recommentation 5. 2 In the case that the abovementioned tests are normal, and the growth anomaly persists, it is recommended to perform IGF1 dosing and a dynamic test for the evaluation of growth hormone secretion. Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1. 5 Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years.

Question no. 2 : From what age and how often is screening for a height growth disorder indicated?

Recommendation 2.1 It is recommended to perform screening for a height growth disorder every six months starting from patient intake, until the completion of height growth and pubertal development.

Strength Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years.

Question no. 5: Which evaluations and examinations are recommended in the case of height growth disorder? Recommendation 5.1 In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: -Pretransfusion Hb; -Phlogosis indicators; -Hepatic and renal function, electrolytes, total proteins, and protein electrophoresis, physical and chemical examination of urine; -Screening for celiac disease (antiTG ± AGA depending on the subject's age, with simultaneous evaluation of IgA); -Thyroid function (FT4, TSH); -Phosphorus-calcium metabolism (calcium, phosphorus, alkaline phosphatase, PTH and vitamin D Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12. 6 In the case of diagnosis of hypogonadotropic hypogonadism, it is recommended to carry out a pituitary MRI to complete the diagnosis.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 13 : In which patients should hormone therapy be started? Recommendation 13.1 In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14. 2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. -Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years.

Question no. 5: Which evaluations and examinations are recommended in the case of height growth disorder? Recommendation 5.1 In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate:

-Pretransfusion Hb; -Phlogosis indicators; -Hepatic and renal function, electrolytes, total proteins, and protein electrophoresis, physical and chemical examination of urine; -Screening for celiac disease (antiTG ± AGA depending on the subject's age, with simultaneous evaluation of IgA); -Thyroid function (FT4, TSH); -Phosphorus-calcium metabolism (calcium, phosphorus, alkaline phosphatase, PTH and vitamin D). Strength of Recommendation: Strong Panel Agreement: Full Recommentation 5. 2 In the case that the abovementioned tests are normal, and the growth anomaly persists, it is recommended to perform IGF1 dosing and a dynamic test for the evaluation of growth hormone secretion.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 5.3 Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12. 6 In the case of diagnosis of hypogonadotropic hypogonadism, it is recommended to carry out a pituitary MRI to complete the diagnosis.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 13 : In which patients should hormone therapy be started? Recommendation 13.1 In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered Panel Agreement: Full Recommendation 7.2 In transition-age patients treated with GH since childhood, it is recommended to repeat the dynamic test after interrupting GH therapy for at least one month, in order to evaluate the need to continue, or not, the therapy at an age-appropriate dosage. -Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years.

Question no. 5: Which evaluations and examinations are recommended in the case of height growth disorder? Recommendation 5.1 In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12. 6 In the case of diagnosis of hypogonadotropic hypogonadism, it is recommended to carry out a pituitary MRI to complete the diagnosis.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 13 : In which patients should hormone therapy be started? Recommendation 13.1 In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 -Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 5: Which evaluations and examinations are recommended in the case of height growth disorder? Recommendation 5.1 In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate:

-Pretransfusion Hb; -Phlogosis indicators; -Hepatic and renal function, electrolytes, total proteins, and protein electrophoresis, physical and chemical examination of urine; Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12. 6 In the case of diagnosis of hypogonadotropic hypogonadism, it is recommended to carry out a pituitary MRI to complete the diagnosis.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 13 : In which patients should hormone therapy be started? Recommendation 13.1 In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonad-Panel Agreement: Full Short stature is a highly predominant condition among individuals affected by thalassemia, with percentages between 8% and 75%. Over the decades, the disorder has undergone a progressive delay in onset, from the first years of life to the teenage period [4] .

The origin of growth disorders in subjects affected by haemoglobinopathy is multifactorial, and includes chronic anaemia, nutritional deficiencies, iron overload, and also iron chelation therapy [3] [4] [5] . For this region, throughout the paediatric age, from patient intake to adult age, it is necessary to establish the active monitoring of height growth in all children affected by haemoglobinopathy.

Monitoring should include not only weight and height, but also all values on appropriate growth curves and growth rate curves, such as WHO curves for non-Caucasian patients (Supplementary Materials), Tanner stage, and genetic target evaluation (height of mother + height of father + 13 cm [if male] − 13 cm [if female]/2).

Every centre must guarantee this first-level evaluation of all paediatric subjects, training personnel in the use of growth curves. Where this evaluation is not possible, the treatment centre should schedule an auxological visit every 6 months or at least once a year, in order to ensure the correct setting of all subjects and early therapy for a disorder that can have long term effects and turns out to be irreversible if not properly treated [3] .

In case of growth disorder, it is necessary to reassess transfusion regimen, iron chelation therapy, and iron overload [6, 7] , and to study associated pathologies, if any, and micronutrient deficiency. Moreover, collaboration with a paediatric endocrinologist for the possible indication of rhGH therapy is needed.

Still controversial points concern diagnostic cut-offs for GH deficiency, priming with sex steroids, starting dose with rhGH, and the definition of therapeutic response [8] [9] [10] [11] .

In writing these recommendations, the panel made reference to the following sources: [3, [8] [9] [10] [11] [12] [13] [14] [15] .

Question no. 9 : From what age and how often is screening for disorders of pubertal development indicated? Recommendation 9.1 It is recommended to perform screening for disorders of pubertal development every six months, starting from puberty, i.e., 12 years, until the completion of pubertal growth. In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: -Pretransfusion Hb; -Phlogosis indicators; -Hepatic and renal function, electrolytes, total proteins, and protein electrophoresis, physical and chemical examination of urine; -Screening for celiac disease (antiTG ± AGA depending on the subject's age, with simultaneous evaluation of IgA); -Thyroid function (FT4, TSH); -Phosphorus-calcium metabolism (calcium, phosphorus, alkaline phosphatase, PTH and vitamin D Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12. 6 In the case of diagnosis of hypogonadotropic hypogonadism, it is recommended to carry out a pituitary MRI to complete the diagnosis.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 13 : In which patients should hormone therapy be started? Recommendation 13.1 In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: -Pretransfusion Hb; -Phlogosis indicators; -Hepatic and renal function, electrolytes, total proteins, and protein electrophoresis, physical and chemical examination of urine; -Screening for celiac disease (antiTG ± AGA depending on the subject's age, with simultaneous evaluation of IgA); -Thyroid function (FT4, TSH); -Phosphorus-calcium metabolism (calcium, phosphorus, alkaline phosphatase, PTH and vitamin D). Strength of Recommendation: Strong Panel Agreement: Full Recommentation 5. 2 In the case that the abovementioned tests are normal, and the growth anomaly persists, it is recommended to perform IGF1 dosing and a dynamic test for the evaluation of growth hormone secretion.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 5. 3 To confirm GH deficiency, it is suggested to use GH-RH arginine, glucagon, or clonidine tests as dynamic tests, depending on the centre's experience. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12. 6 In the case of diagnosis of hypogonadotropic hypogonadism, it is recommended to carry out a pituitary MRI to complete the diagnosis.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 13 : In which patients should hormone therapy be started? Recommendation 13.1 In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12. 6 In the case of diagnosis of hypogonadotropic hypogonadism, it is recommended to carry out a pituitary MRI to complete the diagnosis.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 13 : In which patients should hormone therapy be started? Recommendation 13.1 In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males?

Panel Agreement: Full Question no. 12: Which female patients have a disorder of pubertal development? Recommendation 12.1 Female patients with a lack of thelarche after 13 years of age, or with a lack of pubertal progression in a period of 6-12 months, after a spontaneous beginning of puberty, or with non-appearance of menarche 4 years after the appearance of thelarche or with the non-appearance of menarche by the age of 16 Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years.

Question no. 5: Which evaluations and examinations are recommended in the case of height growth disorder? Recommendation 5.1 In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: -Pretransfusion Hb; -Phlogosis indicators; -Hepatic and renal function, electrolytes, total proteins, and protein electrophoresis, physical and chemical examination of urine; -Screening for celiac disease (antiTG ± AGA depending on the subject's age, with sim- Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism. In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate:

In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism. Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years.

In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.6 Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who do not begin pubertal development, a short 3-6-month cycle of lowdose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism. -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years;

-Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old;

-If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years;

-Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old;

-If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay. -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years;

-Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old;

-If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years.

In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with It is recommended to monitor the response to testosterone therapy through the evaluation of puberty stage, height growth, levels of total testosterone at least every 3-6 months, and of bone age once a year. Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 -Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 -Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males?

Panel Agreement: Full Disorders of pubertal development are among the most frequent complications in paediatric age, with prevalence ranging from 15% [16] to approx. 40% [17] , and clinical pictures varying from puberty delay to the stop of pubertal progression up to hypogonadism [18, 19] . The impact of this complication on the quality of life of teenagers and their parents, on future fertility, and on the development of further complications, is of great significance, and therefore the strict monitoring of its onset is fundamental.

Family history and auxological evaluation, as well as the assessment of pubertal development, are fundamental to contextualising a delay in pubertal development, according to the criteria established in the recommendations.

As for height growth disorders, every centre must ensure a first-level evaluation of all paediatric subjects, training the personnel in the use of growth curves. Where this evaluation is not possible, the treatment centre should schedule an auxological visit every 6 months, or at least once a year.

The most controversial points discussed by the panel concern the choice of the best hormone replacement therapy regimen in boys and girls, and the side effects related to the therapy in the paediatric population.

In writing these recommendations, the panel made reference to the following sources: [8, [20] [21] [22] [23] [24] [25] [26] [27] .

Question no. 19 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength [16] to approx. 40% [17] , and clinical pictures varying from puberty delay to the stop of pubertal progression up to hypogonadism [18, 19] . The impact of this complication on the quality of life of teenagers and their parents, on future fertility, and on the development of further complications, is of great significance, and therefore the strict monitoring of its onset is fundamental.

In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength Patients with primary or secondary amenorrhea with low or inappropriately normal levels of gonadotropins (FSH and LH) and low levels of oestradiol (confirmed by two different tests), after ruling out hyperprolactinemia and interfering drugs, have (secondary or central) hypogonadotropic hypogonadism. Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate:

In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. [16] to approx. 40% [17] , and clinical pictures varying from puberty delay to the stop of pubertal progression up to hypogonadism [18, 19] . The impact of this complication on the quality of life of teenagers and their parents, on future fertility, and on the development of further complications, is of great significance, and therefore the strict monitoring of its onset is fundamental. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism. Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Panel Agreement: Full Recommendation 26.6 It is suggested that one consults a specialist in coagulopathies to consider the introduction of anticoagulants or anti-aggregants in women affected by hypogonadism in hormone replacement therapy and with acknowledged thrombotic risk factors. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 thy, reaching prevalences of over 50% in historical cohorts, and lower but still relevant prevalences in more recent cohorts [1, 16, 28] .

The first element, which is fundamental and easy to assess, consists of the intervals between menstrual cycles, written down in a diary of menstrual cycles that every patient of menstrual age must bring to the treatment centre every 6 months. Primary amenorrhea is defined as the failure to reach menarche by the age of 16, secondary amenorrhea is the absence of a menstrual cycle for ≥3 months in a woman who previously had regular cycles or the absence of menses for ≥6 months in women who previously had irregular cycles, and oligomenorrhea is defined as the occurrence of <9 menstrual cycles/year. This simple and inexpensive evaluation allows for a diagnostic follow-up, with hormone level tests and instrumental investigations, as indicated by the recommendations.

In consideration of the impact of hypogonadism in quality of life, fertility, the development of other endocrine complications and mortality, each treatment centre must guarantee a regular screening for hypogonadism for all women of pre-menopausal age and provide diagnostic and therapeutic follow-up, through the evaluation by a specialist in the case of alterations.

When choosing a treatment that will accompany the patient to the age of physiological menopause, hormone replacement therapy with the administration (preferably transdermally) of 17-β estradiol (that is, the predominant form of endogenous oestrogen) is more advisable because it avoids the first hepatic pass, with a consequent lower impact on the synthesis of angiotensinogen and coagulation factors, and a reduction in thrombotic risk [29] . Progestin is added to oestrogen replacement therapy in a sequential cyclic manner for about 12-14 days a month in non-hysterectomized women. Recently, natural micronized progesterone, made up of smaller particles that facilitate absorption, has come into use for oral (200 mg/day) or intravaginal administration; it is supposed to have better tolerability, lower thrombotic risk, and fewer effects on lipid metabolism as compared to synthetic progestins [30] [31] [32] .

The most controversial points concern the screening of recognised thrombotic risk factors, and the prescription of hormone replacement therapy to women affected by hypogonadism and carriers of thrombotic risk factors. Despite insufficient evidence, the panel suggests screening patients, especially if splenectomised and/or affected by sickle cell disease, testing the most common biomarkers of the prothrombotic state (serum homocysteine, antiphospholipid antibodies, protein C, protein S, resistance to activated protein C, antithrombin), before starting hormone replacement therapy. In order to guarantee correct hormonal support for most women affected by hypogonadism, in particular young women, the panel has considered it more appropriate to suggest a direct involvement of a specialist in coagulopathies, to share the decision-making process before excluding a patient affected by hypogonadism from hormone replacement therapy or starting a long-term therapy with anti-aggregants or anticoagulants, as suggested by some authors [32] .

The best prevention of hypogonadism in female patients affected by thalassemia is early and effective iron chelation. In addition to this, correct lifestyles, like abstention from cigarette smoking and alcohol consumption, correct nutrition, and daily exercise, must be recommended, since they contribute to a reduction in cardiovascular risk [32] .

In writing these recommendations, the panel made reference to the following sources: [3, [32] [33] [34] [35] [36] .

Question no. 29 : From what age and how often is screening for infertility in adult patients indicated?

Recommendation 29.1 It is recommended to perform screening for infertility in all adult female patients wishing to become pregnant in the case of: -history of menstrual cycle alterations and/or previous diagnosis of hypogonadism; -failure to conceive after 12 months of unprotected sexual intercourse in patients with regular menstruation.

Question no. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months. Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength The therapy for infertility includes ovarian stimulation for timed intercourse, intrauterine insemination, and in vitro fertilization with embryo transfer (IVF-ET). It is recommended to evaluate the therapy for infertility case by case, based on the characteristics of the woman, of her partner, and according to the principle of graduality. In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full

In infertile women with hypogonadotropic hypogonadism, it is recommended not to associate GnRH analogs (agonists and antagonists). In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. [17] , and clinical pictures varying from puberty delay to the stop of pubertal progression up to hypogonadism [18, 19] . The impact of this complication on the quality of life of teenagers and their parents, on future fertility, and on the development of further complications, is of great significance, and therefore the strict monitoring of its onset is fundamental. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose.

Panel Agreement: Full Hypogonadism is the first cause of infertility in women with haemoglobinopathy. However, women with regular menstrual cycles may also be infertile. Therefore, patients with transfusion-dependent haemoglobinopathy must be informed of possible fertility limitations, especially if they have developed hypogonadism, and on the diagnostic and therapeutic pathway that should necessarily involve an endocrinologist and a gynaecologist.

The therapy of infertility is based on ovarian stimulation for targeted intercourse, first-level techniques (intrauterine insemination), and second-level techniques (in vitro fertilisation with embryo transfer (IVF-ET). The selection of the technique to be used should always consider the principle of graduality, together with other parameters, such as the age and basic conditions of the woman, the characteristics of the partner, AMH value, and the duration of infertility in women with menstrual cycles [37] [38] [39] [40] [41] .

Ovarian stimulation with gonadotropins can be proposed to infertile women with haemoglobinopathy, where an ovarian response is potentially possible. The possibility of ovarian response, such as in women without haemoglobinopathy, is assessed through antral follicle count in women with a menstrual cycle and with an anti-Mullerian hormone level test in all infertile women, whether they are hypogonadic or not [38, 40] .

Progesterone administration starts at different times, depending on the technique used: 40 h after ovulation induction in the case of targeted intercourse or insemination; between the day of oocyte collection and 3 days after collection in the case of IVF-ET; in any case, it should be continued until the result of a pregnancy test.

The progesterone dose to be used depends on the different modes of administration, namely: 50 mg once a day intramuscularly; 25 mg once a day subcutaneously; 90 mg once a day if using vaginal gel; 200 mg three times a day if micronized progesterone in capsules is employed; 100 mg twice or three times a day if micronized progesterone is used rectally; 400 mg twice a day if vaginal ovules are utilized. The various administration modes can be used indifferently [38, 40] .

The most controversial points concern the use of serial oestradiol dosage in addition to ultrasound monitoring after stimulation with gonadotropins, because there is no conclusive evidence that this approach increases the efficacy and safety of the procedure. The second point regards urine hCG levels suggested to trigger ovulation, varying between 5000 IU and 10,000 IU. However, without conclusive evidence, the 10,000 IU dose is most commonly used in clinical practice by many centres, with specific experience in the treatment of women with haemoglobinopathy.

In writing these recommendations, the panel made reference to the following sources: [3, [38] [39] [40] 42, 43] .

Question no. 39 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced The recommended screening mode consists of an anamnestic and clinical evaluation and testosterone and gonadotropins (FSH, LH) level tests. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonad- In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. Panel Agreement: Full In the population affected by transfusion-dependent thalassaemia the average reported percentage of hypogonadism is 35% to 80%, with important differences in the various case studies depending on the average age of the population studied, on the age at the beginning of transfusion therapy and on the efficacy of chelation therapy [1, 3, 44, 45] .

Signs and symptoms in adult age, when the development of sexual characters is completed, are: reduced psychophysical performance, sexual sphere disorders (reduction of sexual libido and potency), mood alterations, up to more or less advanced signs of muscle hypotrophy, reduction and/or loss of growth of beard and body hair, reduction of bone mineralization indices, with an increased risk of fracture [46] . However, the aspecificity of signs and symptoms and the high prevalence of the disorder impose the need for an annual laboratory screening in all adult subjects.

Serum testosterone assay should be performed on two occasions, on blood collected on an empty stomach, between 7 and 11 a.m., or within 3 h of awakening.

In consideration of the variability of testosterone cut-off values indicated by various guidelines, it is suggested to always refer to laboratory reference parameters. A serum testosterone value is considered definitely normal if >350 ng/dL (12 nmol/L), definitely pathologic, indicating the initiation of replacement therapy, if <230 ng/dL (<8 nmol/L). For intermediate values, in addition to the evaluation of total testosterone, with a repetition of the assay for a confirmation of the value, the estimation (or calculation) of free testosterone is recommended, especially when suspecting altered values of sex hormone binding globulin (SHBG) [47] .

Replacement therapy with testosterone must be proposed to all male patients affected by hypogonadism with the aim of improving psychophysical performance, quality of life and of halting the induction and/or progression of hypogonadism-related damages, especially to the detriment of the bone compartment. However, it is always necessary to evaluate the safety of the therapy, in particular in patients older than 40 years, through PSA test and clinical assessment of prostate morphology.

In thalassemic patients with diagnosed hypogonadism and wish for fertility, the initiation of testosterone replacement therapy is not advised, but rather a gonadotropin therapy should be proposed.

In order to guarantee a correct hormonal support to most males affected by hypogonadism, in particular if young, the panel has considered it more appropriate to suggest a direct involvement of a specialist in coagulopathies to share the decision-making process before excluding a patient with hypogonadism from hormone replacement therapy.

The most controversial points concern the treatment of an aged patient with hypogonadism, in particular if obese or with cardiovascular comorbidities, mainly as far as safety of the therapy, total testosterone cut-off value suggested to start replacement therapy and PSA alarm value for the risk of prostatic carcinoma during testosterone replacement therapy are concerned

In writing these recommendations the panel made reference to the following sources: [ In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay. 

In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 -Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the Panel Agreement: Full Recommendation 52.2 It is recommended against the use of testosterone for the treatment of male infertility.

The most controversial points discussed by the panel concern the choice of the best hormone replacement therapy regimen in boys and girls, and the side effects related to the therapy in the paediatric population.

In writing these recommendations, the panel made reference to the following sources: [8, [20] [21] [22] [23] [24] [25] [26] [27] .

Question no. 19 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay. [16] to approx. 40% [17] , and clinical pictures varying from puberty delay to the stop of pubertal progression up to hypogonadism [18, 19] . The impact of this complication on the quality of life of teenagers and their parents, on future fertility, and on the development of further complications, is of great significance, and therefore the strict monitoring of its onset is fundamental. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 -Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full

Panel Agreement: Full Hypogonadism is the predominant cause of infertility in subjects with transfusiondependent haemoglobinopathy who show dyspermia in approx. 38% of the cases and azoospermia in 18%, and need induction of spermatogenesis with gonadotropins in 12.5% of the cases and assisted fertilization methods in 4.3% [33] .

The medical history must include information regarding present and previous pathologies and therapies, pubertal development, sexual activity, sexually transmitted infections [48, 49] . In the physical examination particular attention should be paid to the virilization state and to secondary sexual characters, dimensions and consistency of the testicles, presence of substantial abnormalities of vasa deferentia and epididymis [50] .

The semen analysis should be carried out according to the methodological indications of the WHO [51] in a certified laboratory and repeated after 2-3 months in case of abnormalities. Indeed, the wide interindividual variability and the overlapping of the values (concentration, motility, and morphology) between fertile and infertile subjects limit the prognostic value of the test and make at least two consecutive tests necessary to define an individual dyspermic (SIA 2016). The cut-off values indicated by the WHO manual are based on the values of a population of fertile males; values below the 5th percentile are considered pathological [52] .

The usual treatment schedule suggests to start with HCG (Human Chorionic Gonadotropin) that, by stimulating Leydig cells, is capable of restoring not only the endocrine function but sometimes also spermatogenesis, in patients who developed hypogonadism in post-pubertal age. The starting dose is 1000 IU of HCG to be administered subcutaneously twice a week, gradually increasing the dose depending on the testosterone levels obtained (checks every 2-4 weeks). The target is to reach plasma testosterone levels within normal limits (and therefore physiological intratesticular levels); an unsatisfactory response to high HCG doses (up to 5000 IU 2-3 times a week) indicates primary gonadal deficiency associated with central hypogonadism.

When no satisfactory improvement of the semen analysis is obtained with HCG alone, in spite of testosterone normalization, FSH should also be administered; as a rule this is necessary in cases of pre-pubertal onset. The initial dose is 75 IU to be administered subcutaneously 2-3 times a week; this dose can be doubled at a later time.

The induction of spermatogenesis usually requires at least 6 months of therapy; there is no indication to continue the treatment beyond 2 years [8, 50] .

Controversial points concern the indication for cryoconservation, that ideally should always be proposed when reaching the adult age, even in patients with sperm quality lower than normal, since the modern techniques of assisted fertilization have definitely increased the possibility of conception even in patients with severe oligoasthenospermia (<1 million spermatozoa/mL) [3] . It is not known whether the use of bisphosphonates during induction of spermatogenesis can have adverse effects, nor is their extent known. In the absence of data, the panel suggests to discontinue their use at least 6 months before conception.

In writing these recommendations the panel made reference to the following sources: [3, [48] [49] [50] .

Question no. 57 Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonad- In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full

Patients with fasting glucose between 100 and 125 mg/dL have impaired fasting glucose (IFG). Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonad- In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay. It is recommended that all patients with puberty delay be referred to an endocrinologist, both in the phase of diagnostic orientation and in the planning phase of therapeutic choices.

Strength of Recommendation: Strong Panel Agreement: Full Disorders of pubertal development are among the most frequent complications in paediatric age, with prevalence ranging from 15% [16] to approx. 40% [17] , and clinical pictures varying from puberty delay to the stop of pubertal progression up to hypogonadism [18, 19] . The impact of this complication on the quality of life of teenagers and their parents, on future fertility, and on the development of further complications, is of great significance, and therefore the strict monitoring of its onset is fundamental. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose.

Panel Agreement: Full Recommendation 62.5 Glycosylated haemoglobin (HbA1c) measurement is not recommended in patients with haemoglobinopathy, either for diabetes diagnosis or for glucose control monitoring.

As a screening mode, it is recommended to evaluate menstrual history at least every six months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 20.2 In the case of oligo/amenorrhea, it is recommended, as a screening mode, to measure plasma levels of FSH, LH, and oestradiol, and to perform a pelvic ultrasound. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. 

Question no. 2: From what age and how often is screening for a height growth disorder indicated?

Recommendation 2.1 It is recommended to perform screening for a height growth disorder every six months starting from patient intake, until the completion of height growth and pubertal development.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. In the case that the abovementioned tests are normal, and the growth anomaly persists, it is recommended to perform IGF1 dosing and a dynamic test for the evaluation of growth hormone secretion. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1

Panel Agreement: Full Alterations of glucose metabolism usually start in the second decade and their prevalence progressively increases with age. Reduced glucose tolerance is common and affects 7% to 24% of patients. Diabetes is reported to have a variable incidence from 0% to 10.5% [1, 53] . This wide variability probably depends on age differences in the investigated patients and on the different chelation possibilities in the countries of origin.

Glucose metabolism disorders connected to iron overload are characterized by specific physiopathology and course of the disease. Insulin deficiency, similarly to type 2 diabetes, is usually relative and not absolute, the onset is generally gradual and insidious and insulin resistance is frequent, like in type II diabetes.

The criteria used for alterations of glucose metabolism in haemoglobinopathies are the same as those proposed for the general population, with the exception of haemoglobin A1c in transfused patients, for whom the validity of the test remains controversial and its use for medium-term monitoring is generally advised against. For these patients, instead, monthly monitoring of fructosamine is indicated [3] .

All patients with glucose metabolism disorders must be adequately instructed on a correct lifestyle (balanced diet, quality of sleep, regular physical activity, quitting smoking). In addition, an intensification of iron chelation therapy is indicated to reach a negative iron balance.

The pharmacological treatment of diabetes mellitus in patients with haemoglobinopathy must be individualized. Oral hypoglycemic drugs can be considered in the early stages of diabetes, before insulin dependence [53] .

The first-choice oral hypoglycemic drug, even in a thalassemic patient with diabetes, is metformin. Other drugs can be added to metformin, including insulin, when necessary. It is reminded that in patients treated with metformin it is useful to check vitamin B12 concentrations (because its absorption can be reduced), particularly in case of anemia worsening [54] .

In the general population with type 2 diabetes it is recommended to introduce new classes of drugs, the efficacy of which has emerged in recent years (glucagon-like peptide-1 [GLP-1] receptor agonists], sodium-glucose cotransporter 2 [SGLT-2] inhibitors, peptidyl peptidase-4 inhibitors). In particular, in patients with atherosclerotic cardiovascular disease or at high cardiovascular risk, and in patients with cardiac decompensation or renal disease, SGLT-2 inhibitors and GLP-1 agonists are recommended, with proven cardiovascular benefit [54] . Data are not yet available on their use in thalassemic patients, and this is a limitation that should be overcome with appropriate studies, to assess their usefulness also in this population of patients.

The decision to initiate insulin therapy in diabetic patients should consider various aspects, like the presence of symptoms typical of diabetes, blood glucose levels, presence of catabolic signs, and C-peptide values.

Early introduction of insulin should be considered in case of hypercatabolism (weight loss), if blood glucose levels remain high and in case of low/undosable C-peptide, a sign of depletion of the pancreatic insulin secretory capacity.

The recommended insulin therapy scheme is the basal/bolus regimen by means of microinjective therapy or with insulin pump, similarly to what indicated in the guidelines for diabetes therapy in the general population [54] .

Fasting blood glucose test is the most effective and straightforward method to screen patients on a regular basis. OGTT can be performed in case of impaired fasting glucose or of severe or persistent iron overload or presence of other risk factors like obesity. As far as HOMA-index (glycemia x insulin level/22.5 where glycemia is expressed in mmol/L and insulin in mUL) is concerned, the drawbacks of this test are multiple, in particular lack of standardization in the insulin level test and lack of data showing that insulin resistance markers predict the response to the therapy. However, since the test is very simple to perform and the development of insulin resistance is a very important event in the physiopathology of glucose metabolism disorders, the panel has indicated HOMA-index among the screening tests to assess insulin resistance. The value of HOMA-index needs to be further assessed for usefulness as a routine test, able to predict diabetes progression.

The patient should be instructed in glycaemic self-monitoring, prevention and recognition and treatment of hypoglycaemia [54] . The evaluation of micro-and macroangiopathic complications is fundamental, as indicated in the guidelines for diabetes in the general population.

Female patients with pre-existing diabetes who become pregnant and those with gestational diabetes should be monitored and treated following the indications contained in the guidelines for pregnant patients [54] .

In writing these recommendations the panel made reference to the following sources: [3,53, In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full

Panel Agreement: Full Recommendation 65.3 It is suggested to repeat screening for hypothyroidism once a month until the 20th week and to perform at least another control between the 26th and the 32nd week of pregnancy. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5

It is recommended to perform screening for hypothyroidism every three months in patients treated with drugs interfering with thyroid function, in particular amiodarone.

Question no. 2: From what age and how often is screening for a height growth disorder indicated? Recommendation 2.1 It is recommended to perform screening for a height growth disorder every six months starting from patient intake, until the completion of height growth and pubertal development.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength Panel Agreement: Full Primary (i.e., of thyroid origin) hypothyroidism is described in 4-18% of patients with Thalassaemia major. The prevalence of hypothyroidism varies in different clinical studies: overt or manifest, characterized by low FT4 and elevated TSH levels in 4-9%, subclinical (elevated TSH, normal FT4) in 12-18%, with a progressive reduction of prevalences in younger cohorts [1, 28, 60, 61] .

The subclinical forms of hypothyroidism, which are the most frequent today, can progress over time to overt forms or can regress, with a normalization of thyroid function; therefore they need an adequate follow-up [1, [62] [63] [64] .

The forms of central hypothyroidism, secondary to pituitary deficiency of TSH, are more infrequent [65] . The biochemical diagnosis is based on the finding of low FT4 with low or inappropriately normal TSH for FT4 values. The recognition of these forms is however increasing as the years go by, suggesting that a damage of the TRH-TSH axis from hypothalamic-pituitary hemosiderosis can become apparent over the years in older patients and in subjects with lower ferritin levels than those of patients who have already developed primary hypothyroidism.

Primary hypothyroidism in overt form must always be treated [66, 67] . The therapy objective in primary hypothyroidism is to maintain TSH in the normal range for age, avoiding TSH suppression, a sign of overdosage, that entails an increased risk of atrial fibrillation and osteoporosis.

Subclinical forms, once confirmed, often take advantage of the therapy, in particular in young and adult patients, when TSH > 10 µU/mL, in the presence of subjective symptoms; anyway, the therapy must be assessed individually in the clinical context of the single patient; in any case in untreated patients the thyroid function should be monitored over time (every six months) for the possible evolution of a subclinical hypothyroidism into overt hypothyroidism [62] . Subclinical hypothyroidism should be treated in female patients seeking pregnancy or during pregnancy. As for subclinical hypothyroidism diagnosed in old patients (see dedicated chapter), in the general population the treatment does not seem to be convenient in patients over 70 years and is contraindicated over 80 [62] [63] [64] ). Anyway, follow-up for the possible evolution into frank hypothyroidism is always indicated.

Replacement therapy of primary hypothyroidism consists in oral administration of synthetic L-thyroxine, starting with low doses, that will be adjusted later on based on TSH levels. In adult patients, initial doses of 25-50 mcg/day are indicated, whereas in cardiopathic patients the dose is of 12.5 mcg/day, with subsequent adjustments based on the test and the clinical response [66, 67] .

In cases of difficulty in reaching the TSH target, the factors that might affect efficacy, stability and simplicity of the therapy should be evaluated and a possible different drug formulation with less absorption problems (oral liquid thyroxine or soft capsules) should be considered.

In every thalassemic patient seeking pregnancy or planning to enter a medically assisted reproduction program, thyroid function should also be checked. The panel believes that the exposure to the toxic effects of transfusional iron should be considered as a "thyroid fragility" and for pregnant thalassemic women recommends the monitoring scheme provided for by the guidelines on thyropathies during pregnancy [68] , with monthly control of FT4 and TSH levels until the 20th week of gestation and at least another control between the 26th and the 32nd week.

In patients already treated for hypothyroidism before pregnancy, it is advised to adjust the dosage of L-thyroxine so as to have a TSH value within 2.5 µU/mL before conception. To meet the increased needs during pregnancy, the L-thyroxine dosage should be increased already starting from the 4th week, and then adjusted based on the tests, periodically checking FT4 and TSH levels throughout pregnancy (once a month until the 20th week and at least another control between the 26th and the 32nd week). After delivery, the need for L-thyroxin decreases as compared to pregnancy, therefore the therapy should be returned to pre-conception levels and then adjusted depending on TSH and FT4 levels, tested about 6 weeks after delivery [68] .

In writing these recommendations the panel made reference to the following sources: [3, [61] [62] [63] [65] [66] [67] [68] [69] .

Question no. 75 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full

It is recommended that calcium value be kept at the lower limits of the range, phosphorus values at the upper limits of the range, a serum calcium-phosphate (both measured in mg/dL) product < 55 mg 2 /dL 2 (4.4 mmol 2 /L 2 ), avoiding hypercalciuria, nephrolithiasis and nephrocalcinosis. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 -Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months. A calcium concentration < 8.0 mg/dL (<2.0 mM) associated with frankly low or inappropriately normal PTH values (<15 ng/L) are the diagnostic criteria of postoperative hypoPTH [71] , that the panel has considered valid also in haemoglobinopathies, since both the toxic effect of iron and the postoperative devascularization of the glands left in situ induce a permanent functional damage to parathyroids.

Technical limitations related to measurement of ionized calcium make the use of calcium corrected for albumin preferable to diagnose hypocalcemia [72] . For each reduction of 1 g/dL in albumin value, calcium value should be increased by 0.8 mg/dL [72] .The formula utilized to calculate calcium corrected for albumin is: corrected calcium = measured calcium + [(4.0 − albumin) × 0.8] [73, 74] .

Hypocalcemia and chronic hyperphosphatemia cause greater neuromuscular and cardiac irritability and neuropsychiatric and cognitive disorders, such as facial paresthesias or paresthesias of the extremities, muscle pain and weakness, anxiety, depression, emotional lability, concentration difficulty, «brain fog», prolongation of correct QT in the ECG. Patients with chronic hypoPTH can develop kidney stones and nephrocalcinosis, brain calcifications (especially of the basal ganglia), calcifications at articular, cutaneous, ocular, and vascular level [71, 72] .

Even though hypoPTH in patients with haemoglobinopathy is a chronic condition that develops progressively, the possibility of acute-onset hypocalcaemia should be considered in patients with symptoms of variable severity, from mild paresthesias (typically peribuccal and distal), muscle spasms and cramps, myalgias to tetanic crises, laryngospasm and convulsions [72] . In this case an emergency therapy should be established with i.v. administration of calcium gluconate [72, 73] , integrated by oral administration of calcium and calcitriol.

Calcium carbonate is the first-choice product for calcium supplementation, because it contains 40% elemental calcium and is the most inexpensive. The more expensive calcium citrate, containing 20% elemental calcium, is employed in case of achlorhydria or during treatment with proton-pump inhibitors or in case of constipation secondary to intake of calcium carbonate [73] .

The dosage of supplemental calcium varies greatly from subject to subject, generally from 1 to 3 g altogether, divided into two or three daily doses [73] . Since a dose of 500 mg of calcium saturates intestinal calcium uptake, it is not useful to prescribe very high single doses, whereas dose splitting is more beneficial [74] .

The formulation of choice in hypoparathyroidism is the active form of vitamin D, calcitriol (1.25-OH vitamin D), which is insufficient due to the deficiency of PTH-dependent renal 1α-hydroxylation of 25OH vitamin D. Calcitriol should be preferred to vitamin D2 or D3 (ergocalciferol or cholecalciferol), because these latter agents should be used at very high dosages with the risk of severe intoxication even in the long term, due to their long halflife [73] . Calcitriol (1.25OH vitamin D), does not cross-react in dosages of 25OH vitamin D. In addition to calcitriol, it is suggested to utilize also oral formulations of vitamin D2 (ergocalciferol) or D3 (cholecalciferol) with physiological dosage, in order to keep the dosage of 25OH vitamin D at the lower limits of the normal range, because of the beneficial effects on the skeletal and other body tissues.

The use of higher doses of calcitriol can reduce the calcium dosages necessary to prevent hypocalcaemia [72] .

Recombinant PTH analogs are indicated in severe chronic hypoparathyroidism with inadequate control of calcaemia, in spite of therapy with high doses of calcium (>2.5 g a day) and calcitriol (>1.5 micrograms a day), development of hypercalciuria, urinary stone disease, nephrocalcinosis, reduction of glomerular filtrate, hyperphosphatemia, gastrointestinal disorders associated with absorption, reduced quality of life. In 2015 FDA and in 2017 EMA approved the use of PTH intact analog (1-84) for the treatment of hypoPTH not controlled by conventional therapy, in the absence of contraindications (hypersensitivity to the active substance or to one of the excipients, ongoing or previous skeletal radiotherapy, malignant neoplasms of the skeleton or bone metastases, patients with increased risk of osteosarcoma, such as patients with Paget disease or with genetic bone diseases, patients with unexplained increase in bone alkaline phosphatase).

In writing these recommendations the panel made reference to the following sources: [3, 72, 73, [75] [76] [77] . In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonad- In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength [17] , and clinical pictures varying from puberty delay to the stop of pubertal progression up to hypogonadism [18, 19] . The impact of this complication on the quality of life of teenagers and their parents, on future fertility, and on the development of further complications, is of great significance, and therefore the strict monitoring of its onset is fundamental.

In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is tes-

In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with In patients with adrenal insufficiency on replacement therapy, it is recommended to perform clinical monitoring and to test sodium and potassium levels at least every 6 months.

Question no. 2: From what age and how often is screening for a height growth disorder indicated? Recommendation 2.1 It is recommended to perform screening for a height growth disorder every six months starting from patient intake, until the completion of height growth and pubertal development.

Strength Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. -Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose.

Panel Agreement: Full Adrenal insufficiency in patients affected by haemoglobinopathy is mainly secondary to iron accumulation in the pituitary gland and, to a probably less relevant extent, in the adrenal cortex [78] . The studies published so far report highly variable prevalences (from 4% to 50%), because of the variability in the cohorts observed and in the methods of diagnosis [33, [79] [80] [81] .Recent data indicate that the diagnostic criteria for adrenal insufficiency identified in the general population are not suitable for subjects affected by haemoglobinopathy and for polytransfused patients, since they are not related to a significant clinical impact [81] . For this reason, with reference to the acquired clinical experience and to the lack of conclusive scientific evidence, the panel suggests to use a cortisol cutoff < 10 mcg/dL to indicate stimulus test with ACTH. The panel suggests considering a stimulus test with ACTH in patients with cortisol values between 10 and 15 mcg/dL case by case, in relation to the anamnestic picture, in particular history of iron overload and coexistence of other hypothalamic-pituitary deficiencies, and to the clinical picture, in case of reduction of physical performance and blood pressure.

The therapy for adrenal insufficiency consists of the administration of glucocorticoids. Adrenal production is influenced by age, gender, and body composition, with average values recognized in approx. 5-8 mg/m 2 a day, corresponding to an oral dose of about 15-25 mg a day of hydrocortisone or 20-35 mg of cortisone acetate in adults [82] .

The therapy must be individualized, especially based on the clinical response (quality of life, improvement of asthenia and mood), blood pressure values, and serum electrolyte levels. The evaluation must pay particular attention to a precise individualization of the therapy, in order to avoid a dangerous overtreatment that can have important repercussions, especially on metabolism and bones, and in consideration of the chronicity of the therapy itself. To better reproduce the physiological curve of endogenous production, a first administration is recommended at awakening, followed by a second dose (approx. 50% of the first one) early in the afternoon. Usual treatment schedules consist in hydrocortisone, 10-15 mg/day, or cortisone acetate, 25-37.5 mg/day, divided into at least 2 daily doses. In some selected cases, it might be beneficial to divide it into three doses, the third of which, lower than the previous ones, late in the afternoon, but not too close to evening rest time.

In order to prevent the onset of adrenal insufficiency crises, it is fundamental to instruct patients and relatives on the need to increase cortisone replacement therapy (temporarily doubling or tripling the habitual dose) in case of intercurrent diseases, fever, vomit, gastroenteritis, drop in blood pressure, stressful situations, resorting to injectable hydrocortisone in emergency situations or in the impossibility to adequately take/absorb the oral drug (for example in case of acute gastroenteritis), and on the need for coverage with parenteral hydrocortisone in case of surgical interventions and during labor.

Still controversial points concern the most reliable stimulus test for diagnosis and the most effective diagnostic cut-off values for the population with haemoglobinopathy.

In writing these recommendations the panel made reference to the following sources: [82] [83] [84] [85] [86] [87] .

Question no. 91 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Panel Agreement: Full Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. It is recommended that all patients with puberty delay be referred to an endocrinologist, both in the phase of diagnostic orientation and in the planning phase of therapeutic choices.

Strength of Recommendation: Strong Panel Agreement: Full Disorders of pubertal development are among the most frequent complications in paediatric age, with prevalence ranging from 15% [16] to approx. 40% [17] , and clinical pictures varying from puberty delay to the stop of pubertal progression up to hypogonadism [18, 19] . The impact of this complication on the quality of life of teenagers and their parents, on future fertility, and on the development of further complications, is of great In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose. In the case that the abovementioned tests are normal, and the growth anomaly persists, it is recommended to perform IGF1 dosing and a dynamic test for the evaluation of growth hormone secretion.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 5.3 To confirm GH deficiency, it is suggested to use GH-RH arginine, glucagon, or Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the Panel Agreement: Full Question no. 95 : In which patients should hormone replacement therapy be initiated? Recommendation 95.1 It is suggested to initiate replacement therapy with biosynthetic GH only in presence of GH deficiency within an appropriate clinical context, proven according to the parameters indicated and in the absence of contraindications.

In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In patients with GH deficiency in replacement therapy it is recommended to perform thyroid function assessment 6 months after the beginning or the change of GH therapy. Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose.

Panel Agreement: Full The reported frequency of GH deficiency in adult patients with thalassaemia major varies from 8% to 44% [88] .

IGF-1 dosage is the first biochemical screening test for GH deficiency, even if its result is altered also for other reasons, such as hepatopathy (due to both iron accumulation and hepatitis viruses), chronic anemia, increase in inflammatory cytokines, malnutrition and GH resistance. In case of significanty reduced IGF-1, indicatively < −2 SD as compared to normal values for age and gender, for the dosage method used [89] , stimulus test for GH is indicated.

There are no indications establishing the modality and frequency to assess GH/IGF-1 axis in adult subjects with haemoglobinopathy explicitly and univocally. The panel has suggested an annual evaluation of IGF-1 in all patients with haemoglobinopathy, with subsequent stimulus test in case of abnormal IGF-1 value.

The traditional stimulus test for GH has been the insulin hypoglycaemia test; today this is not much used because of the risks related to the induction of hypoglycaemia, in particular in fragile subjects. The most widely used test is the stimulus test with GHRH + Arginine, whose results should be interpreted considering the patient's age and BMI. The GHRH + Arginine test is a very powerful stimulus, that also acts directly at pituitary level and therefore may fail to identify a GH deficiency of hypothalamic origin.

Anyway, in case of GH deficiency, it is advised to check global pituitary functionality and to perform hypothalamic-pituitary imaging (preferably RMI).

In adult patients with GHD the therapy improves cardiovascular function, physical exercise capacity and quality of life, increases lean body mass and bone mineral density [34] .

GH dosage must be individualized; since a possible side effect is liquid retention that is dose-dependent, it is advisable to start with low doses to be increased later on depending on clinical response, possible side effects, and IGF-1 levels. The initial suggested dose in the adult is 0.2 mg/day subcutaneously in males (in the evening) and 0.3 mg/day in females.

The subsequent dosage increments should be individualized based on clinical and biochemical response, with the aim of maintaining IGF-1 in the lower half of the normal range for age and gender [34, 90] .

In writing these recommendations the panel made reference to the following sources: [33, 34, 88, [90] [91] [92] .

Question no. 98: How should endocrinopathies be managed and monitored in subjects in late adulthood affected by haemoglobinopathies?

Recommendation 98.1 It is suggested to continue with hormone testing to recognize the onset of new endocrine complications even in middle/late adulthood, according to what described in previous chapters for the various hormonal axes.

In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13.3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose.

Panel Agreement: Full The clinical history of thalassemic patients has changed over time thanks to the improvement of specific therapies; thus, patients can reach advanced adulthood and thalassaemia has become an "open"-prognosis disease.

Ageing is therefore a new frontier for thalassemic patients. Moreover, adult thalassemic patients may develop the pathologies usually affecting general population later in life at a younger age [93] .

In patients already affected by known endocrine pathologies, it is necessary to continue follow up and therapy controls, similarly to what is done for adult patients (see chapters dedicated to the various hormonal axes). Hormone replacement therapies in late adulthood shall be modulated and the dosages adjusted based on patients' age and clinical picture, similarly to what described in the Guidelines for general population. As there are currently no specific studies on changes in hormone therapies in old thalassemic population, the panel suggests to follow the directions known for general population.

Furthermore, with advancing age and the presence of concurrent pluripathologies, the patient takes more and more drugs, and the possible interference of the other drugs taken for concurrent pathologies on the various hormonal axes and on endocrine replacement therapies have to be considered.

In writing these recommendations the panel made reference to the following sources: [8, 32, 33, 67, 69, 81, [93] [94] [95] [96] [97] [98] .

Question no. 99: How should screening for endocrinopathies in subjects with nontransfusion dependent haemoglobinopathies be performed? Recommendation 99.1 It is suggested to evaluate: -every six months, starting from patient intake: weight, height, BMI, height when sitting, growth rate, Tanner stage, genetic target; -every year starting from 10 years of age: fasting blood sugar levels, TSH, FT4, serum calcium corrected for albumin value, serum phosphorus; -every six months in females starting from menarche: menstrual calendar in women; -every year in males starting from 18 years of age: testosterone, FSH, LH; -in cases of history of iron accumulation and other endocrine deficiencies: sodium, potassium, ACTH, cortisol levels in the morning (8 a.m.); -in women with oligo/amenorrhea, hypogonadism or failure to conceive after 12 months of unprotected sexual intercourse: FSH, LH, oestradiol, prolactin, gynaecological visit, pelvic ultrasound, hysterosalpingography, PAP test; -in men with hypogonadism or failure to conceive after 12 months of unprotected sexual intercourse: semen analysis on an adequately collected sample Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.

Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.

Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.

Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months.

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 14.2 In the case of non-response to the first cycle, it is suggested to consider a second cycle of treatment with an increase of 25-50 mg compared to the first dose.

In haemoglobinopathies not on a regular transfusion regimen, like non transfusiondependent thalassaemias (NTDT) and sickle cell disease (SCD), prevalence data of endocrine complications are not conclusive and indications on screening and monitoring modalities are not clearly established.

Although in non transfusion-dependent haemoglobinopathies endocrine complications are less frequent than in subjects on a regular transfusion regimen from the first years of their lives, it is however evident that the prevalence of these complications is higher than in general population, with a further increase linked to advancing age [99, 100] .

For this reason also non transfusion-dependent subjects should be monitored regularly for the onset of endocrine disorders.

For NTDT an annual screening for major endocrine deficiencies is recommended starting from 10 years of age [100] . There are no specific indications for monitoring of endocrinopathies in subjects with SCD [101] [102] [103] .

According to what reported in the present document, first-level screening for endocrinopathies is based on clinical and laboratory tests that can be performed during routine checks for the primary disease. The panel recommends regular first-level screening in non-transfusion dependent subjects, similarly to what indicated for transfusion-dependent patients, considering the poor specificity of signs and symptoms of endocrine complications, the asymptomaticity of some disorders and the negative evolution of the primary disease when some endocrine complications are present.

In case of an endocrine complication, non transfusion-dependenti subjects must receive the same therapy and clinical monitoring as non transfusion-dependent ones, as indicated in the present document.

In writing these recommendations the panel made reference to the following sources: [99, 100, [103] [104] [105] [106] [107] [108] [109] [110] . Acknowledgments: Authors thank the two independent experts who revised the document, Maria Rosaria Ambrosio, Maria Domenica Cappellini, and the patient representative of Associazione per la Lotta alla Talassemia Rino Vullo.

The authors declared not to have any financial, professional or other kinds of conflicts of interest related to the topics dealt with in the present document.

Note for Users: The present Good Pratice (GP) document is the tool through which the knowledge developed by biomedical research is transferred to daily clinical practice. GP is based on the international standards of analysis to which they refer in a critical and contextualized manner: these standards must be able to express themselves, for each individual case, on the basis of available clinical information, preferences expressed by patients and other contextual situations, accurately examined in light of the expertise of healthcare professionals. It is therefore up to the expertise and judgement of the professionals, who carefully listen to particular requests and consider the values expressed by patients, to establish which procedures or treatments are more appropriate to manage individual clinical cases.

Agreement: Full Question no

Patients with reduced cortisol and high ACTH levels have primary adrenal insufficiency

Height and Growth Disorder Question no. 2: From what age and how often is screening for a height growth disorder indicated?

Strength of Recommendation: Strong Panel Agreement: Full Question no. 3: How should screening for height growth disorders be performed? auxological evaluation (weight, height, BMI, height when sitting, growth rate, Tanner stage) carried out every six months, plotting all values on appropriate growth curves (curves of Cacciari for Italian patients, WHO for non-Caucasian patients) and comparing them to the genetic target

GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. Strength of Recommendation: Strong Panel Agreement: Full Question no. 5: Which evaluations and examinations are recommended in the case of height growth disorder? Recommendation 5.1 In patients with height growth disorders

Hepatic and renal function, electrolytes, total proteins, and protein electrophoresis, physical and chemical examination of urine; -Screening for celiac disease (antiTG ± AGA depending on the subject's age, with sim-Strength of Recommendation: Strong

Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay

Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism

In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months

In the presence of primary adrenal insufficiency, adrenal imaging (CT or RMI) is suggested

2022, 11, x FOR PEER REVIEW

Full of gonadotropins, as an alternative to testosterone, only for the induction of testicular growth, starting from the age of 14

Strength of Recommendation: Strong Panel Agreement: Full of Recommendation: Strong Panel Agreement: Full Question no. 16: How should male patients with puberty delay under treatment be monitored?

It is recommended to monitor the response to testosterone therapy through the evaluation of puberty stage, height growth, levels of total testosterone at least every 3-6 months, and of bone age once a year. Strength of Recommendation: Strong Panel Agreement: Full Strength of Recommendation: Conditioned

Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay

Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism

In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months

Height and Growth Disorder Question no. 2: From what age and how often is screening for a height growth disorder indicated?

Strength of Recommendation: Strong Panel Agreement: Full Question no. 3: How should screening for height growth disorders be performed? auxological evaluation (weight, height, BMI, height when sitting, growth rate, Tanner stage) carried out every six months, plotting all values on appropriate growth curves (curves of Cacciari for Italian patients, WHO for non-Caucasian patients) and comparing them to the genetic target

GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. Strength of Recommendation: Strong Panel Agreement: Full Question no. 5: Which evaluations and examinations are recommended in the case of Strength of Recommendation: Strong

Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay

Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism

In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried Panel Agreement: Full

Height and Growth Disorder Question no. 2: From what age and how often is screening for a height growth disorder indicated?

Strength of Recommendation: Strong Panel Agreement: Full Question no. 3: How should screening for height growth disorders be performed? auxological evaluation (weight, height, BMI, height when sitting, growth rate, Tanner stage) carried out every six months, plotting all values on appropriate growth curves (curves of Cacciari for Italian patients, WHO for non-Caucasian patients) and comparing them to the genetic target

GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive Strength of Recommendation: Strong

Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay

Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism

Height and Growth Disorder Question no. 2: From what age and how often is screening for a height growth disorder indicated?

Strength of Recommendation: Strong Panel Agreement: Full Question no. 3: How should screening for height growth disorders be performed? auxological evaluation (weight, height, BMI, height when sitting, growth rate, Tanner stage) carried out every six months, plotting all values on appropriate growth curves (curves of Cacciari for Italian patients, WHO for non-Caucasian patients) and comparing them to the genetic target

GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years

2022, 11, x FOR PEER REVIEW laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism

Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay

Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism

Height and Growth Disorder Question no. 2: From what age and how often is screening for a height growth disorder indicated?

Strength of Recommendation: Strong Panel Agreement: Full Question no. 3: How should screening for height growth disorders be performed? auxological evaluation (weight, height, BMI, height when sitting, growth rate, Tanner stage) carried out every six months, plotting all values on appropriate growth curves (curves of Cacciari for Italian patients, WHO for non-Caucasian patients) and comparing them to the genetic target

Strength of Recommendation: Strong J. Clin. Med. 2022, 11, x FOR PEER REVIEW

92: How often should screening for GH deficiency be performed?

2022, 11, x FOR PEER REVIEW

Full of gonadotropins, as an alternative to testosterone, only for the induction of testicular growth, starting from the age of 14

Strength of Recommendation: Strong Panel Agreement: Full of Recommendation: Strong Panel Agreement: Full Question no. 16: How should male patients with puberty delay under treatment be monitored?

It is recommended to monitor the response to testosterone therapy through the evaluation of puberty stage, height growth, levels of total testosterone at least every 3-6 months, and of bone age once a year. Strength of Recommendation: Strong Panel Agreement: Full Question no. 17: How should female patients with puberty delay under treatment be monitored?

height growth, and the dimensions of the uterus and ovaries with an ultrasound scan at least every 3-6 months, and of bone age once a year. Strength of Recommendation: Strong Panel Agreement: Full of Recommendation: Strong Panel Agreement: Full Question no. 18: Which patients should be evaluated by the endocrinologist? of Recommendation: Strong Panel Agreement: Full Disorders of pubertal development are among the most frequent complications in paediatric age

Screening for celiac disease (antiTG ± AGA depending on the subject's age, with simultaneous evaluation of IgA)

-Thyroid function

Strength of Recommendation: Strong Panel Agreement: Full Recommentation 5.2 In the case that the abovementioned tests are normal, and the growth anomaly per-Strength of Recommendation: Strong

2022, 11, x FOR PEER REVIEW

Full of gonadotropins, as an alternative to testosterone, only for the induction of testicular growth, starting from the age of 14

Strength of Recommendation: Strong Panel Agreement: Full of Recommendation: Strong Panel Agreement: Full Question no. 16: How should male patients with puberty delay under treatment be monitored?

It is recommended to monitor the response to testosterone therapy through the evaluation of puberty stage, height growth, levels of total testosterone at least every 3-6 months, and of bone age once a year. Strength of Recommendation: Strong Panel Agreement: Full Strength of Recommendation: Conditioned

Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay

Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism

In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months

Height and Growth Disorder Question no. 2: From what age and how often is screening for a height growth disorder indicated?

Strength of Recommendation: Strong Panel Agreement: Full Question no. 3: How should screening for height growth disorders be performed? auxological evaluation (weight, height, BMI, height when sitting, growth rate, Tanner stage) carried out every six months, plotting all values on appropriate growth curves (curves of Cacciari for Italian patients, WHO for non-Caucasian patients) and comparing them to the genetic target

GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years

Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old

Strength of Recommendation: Strong Panel Agreement: Full Question no. 5: Which evaluations and examinations are recommended in the case of height growth disorder? Recommendation 5.1 Strength of Recommendation: Strong

2022, 11, x FOR PEER REVIEW laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism

Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay

Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism

it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months. Strength of Recommendation: Conditioned Panel Agreement: Full laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism

Panel Agreement: Full Question no. 97: Which patients should be evaluated by the endocrinologist?

Height and Growth Disorder Question no. 2: From what age and how often is screening for a height growth disorder indicated?

Strength of Recommendation: Strong Panel Agreement: Full Question no. 3: How should screening for height growth disorders be performed? auxological evaluation (weight, height, BMI, height when sitting, growth rate, Tanner stage) carried out every six months, plotting all values on appropriate growth curves (curves of Cacciari for Italian patients, WHO for non-Caucasian patients) and comparing them to the genetic target

GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. Strength of Recommendation: Strong Panel Agreement: Full Question no. 5: Which evaluations and examinations are recommended in the case of height growth disorder? Recommendation 5.1 In patients with height growth disorders

Hepatic and renal function, electrolytes, total proteins, and protein electrophoresis, physical and chemical examination of urine; -Screening for celiac disease (antiTG ± AGA depending on the subject's age, with simultaneous evaluation of IgA)

-Thyroid function

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 5.3 To confirm GH deficiency, it is suggested to use GH-RH arginine, glucagon, or clonidine tests as dynamic tests, depending on the centre's experience. Strength of Recommendation: Strong Panel Agreement: Full Strength of Recommendation: Strong

2022, 11, x FOR PEER REVIEW

2022, 11, x FOR PEER REVIEW laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism

Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay

Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in Panel Agreement: Full

2022, 11, x FOR PEER REVIEW

2022, 11, x FOR PEER REVIEW laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism

Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay

2022, 11, x FOR PEER REVIEW

Full of gonadotropins, as an alternative to testosterone, only for the induction of testicular growth, starting from the age of 14

Strength of Recommendation: Strong Panel Agreement: Full of Recommendation: Strong Panel Agreement: Full Question no. 16: How should male patients with puberty delay under treatment be monitored?

It is recommended to monitor the response to testosterone therapy through the evaluation of puberty stage, height growth, levels of total testosterone at least every 3-6 months, and of bone age once a year. Strength of Recommendation: Strong Panel Agreement: Full Question no. 17: How should female patients with puberty delay under treatment be monitored?

and the dimensions of the uterus and ovaries with an ultrasound scan at least every 3-6 months, and of bone age once a year. Strength of Recommendation: Strong Panel Agreement: Full of Recommendation: Strong Panel Agreement: Full Question no. 18: Which patients should be evaluated by the endocrinologist? of Recommendation: Strong Panel Agreement: Full Disorders of pubertal development are among the most frequent complications in paediatric age, with prevalence ranging from 15% [16] to approx. 40% [17], and clinical pictures varying from puberty delay to the stop of pubertal progression up to hypogonadism

Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay

Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism

it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months. Strength of Recommendation: Conditioned Panel Agreement: Full laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism

It is suggested to assess the possible interference of other drugs, taken by patients for concurrent pathologies, on the various hormonal axes and on endocrine replacement therapies

2022, 11, x FOR PEER REVIEW

Full of gonadotropins, as an alternative to testosterone, only for the induction of testicular growth, starting from the age of 14

Strength of Recommendation: Strong Panel Agreement: Full of Recommendation: Strong Panel Agreement: Full Question no. 16: How should male patients with puberty delay under treatment be monitored?

It is recommended to monitor the response to testosterone therapy through the evaluation of puberty stage, height growth, levels of total testosterone at least every 3-6 months, and of bone age once a year. Strength of Recommendation: Strong Panel Agreement: Full Question no. 17: How should female patients with puberty delay under treatment be monitored?

height growth, and the dimensions of the uterus and ovaries with an ultrasound scan at least every 3-6 months, and of bone age once a year. Strength of Recommendation: Strong Panel Agreement: Full of Recommendation: Strong Panel Agreement: Full Question no. 18: Which patients should be evaluated by the endocrinologist? of Recommendation: Strong Panel Agreement: Full Disorders of pubertal development are among the most frequent complications in paediatric age

2022, 11, x FOR PEER REVIEW

Strength of Recommendation: Strong Panel Agreement: Full Question no. 15: Which is the hormone therapy for puberty delay in females? Strength of Recommendation: Conditioned J. Clin. Med. 2022, 11, x FOR PEER REVIEW laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism

Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay

Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism

Height and Growth Disorder Question no. 2: From what age and how often is screening for a height growth disorder indicated?

Strength of Recommendation: Strong Panel Agreement: Full Question no. 3: How should screening for height growth disorders be performed? auxological evaluation (weight, height, BMI, height when sitting, growth rate, Tanner stage) carried out every six months, plotting all values on appropriate growth curves (curves of Cacciari for Italian patients, WHO for non-Caucasian patients) and comparing them to the genetic target. Strength of Recommendation: Strong

Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones

Panel Agreement: Full Question no. 100: Which is the therapy for endocrinopathies in subjects with non transfusion-dependent haemoglobinopathy?

It is recommended to perform the therapy and clinical and laboratory monitoring provided for in the present document for transfusion-dependent subjects

Height and Growth Disorder Question no. 2: From what age and how often is screening for a height growth disorder indicated?

Strength of Recommendation: Strong Panel Agreement: Full Question no. 3: How should screening for height growth disorders be performed? auxological evaluation (weight, height, BMI, height when sitting, growth rate, Tanner stage) carried out every six months, plotting all values on appropriate growth curves (curves of Cacciari for Italian patients, WHO for non-Caucasian patients) and comparing them to the genetic target

GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. Strength of Recommendation: Strong Panel Agreement: Full Question no. 5: Which evaluations and examinations are recommended in the case of height growth disorder? Recommendation 5.1 In patients with height growth disorders

Hepatic and renal function, electrolytes, total proteins, and protein electrophoresis, physical and chemical examination of urine; -Screening for celiac disease (antiTG ± AGA depending on the subject's age, with simultaneous evaluation of IgA)

-Thyroid function

Strength of Recommendation: Strong Panel Agreement: Full Recommendation 5.3 To confirm GH deficiency, it is suggested to use GH-RH arginine, glucagon, or clonidine tests as dynamic tests, depending on the centre's experience. Strength of Recommendation: Strong Panel Agreement: Full Strength of Recommendation: Strong

Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: A risk assessment study from a multi-center nation-wide cohort

Architettura Della Rete Italiana Talassemie Ed Emoglobinopatie

Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)

Critical appraisal of growth retardation and pubertal disturbances in thalassemia: Growth and pubertal disturbances in thalassemia

Predicting factors for liver iron overload at the first magnetic resonance in children with thalassaemia major

Multiparametric Cardiac Magnetic Resonance Survey in Children with Thalassemia Major: A Multicenter Study

Prospective CMR Survey in Children with Thalassemia Major

Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines

Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence

Growth hormone therapy for people with thalassaemia

Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective

Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency

Consensus Guidelines for the Diagnosis and Treatment of Growth Hormone (GH) Deficiency in Childhood and Adolescence: Summary Statement of the GH Research Society

Human Growth Hormone (Somatropin) for the Treatment of Growth Failure in Children-Technology Appraisal Guidance

Growth hormone (GH) deficiency in patients with β-thalassemia major and the efficacy of recombinant GH treatment

Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major: Endocrine function during DFX therapy in TM

Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: A multicenter study by the Thalassaemia International Federation (TIF)

Thalassaemia and aberrations of growth and puberty

Hypogonadism in thalassemia major patients

Hypogonadism in male thalassemia major patients: Pathophysiology, diagnosis and treatment

The experience of a tertiary unit on the clinical phenotype and management of hypogonadism in female adolescents and young adults with transfusion dependent thalassemia

Management of hypogonadism from birth to adolescence

Androgens during Infancy, Childhood, and Adolescence: Physiology and Use in Clinical Practice

Delayed Puberty

Paediatric and adult-onset male hypogonadism

Guidelines for the Standard Monitoring of Patients with Thalassemia: Report of the Thalassemia Longitudinal Cohort

Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: Incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre

Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause

The British Menopause Society and Women's Health Concern recommendations on the management of women with premature ovarian insufficiency

Clinical Management of Congenital Hypogonadotropic Hypogonadism

Review and Recommendations on Management of Adult Female Thalassemia Patients with Hypogonadism based on Literature Review and Experience of Icet-A Network Specialists

An ICET-A survey on occult and emerging endocrine complications in patients with β-thalassemia major: Conclusions and recommendations

Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline

Approach to the Patient with Hypogonadotropic Hypogonadism

Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline

Reproductive health issues in female patients with beta-thalassaemia major: A narrative literature review

ESHRE PGT Consortium good practice recommendations for the organisation of PGT

Haemoglobinopathy: Considerations for reproductive health

Fertility: Assessment and Treatment for People with Fertility Problems; National Institute for Health and Clinical Excellence: Guidance; Royal College of Obstetricians & Gynaecologists: London, UK

Norme in Materia di Procreazione Medicalmente Assistita. Legge

Pregnancy in Thalassemia

Gonadal dysfunction in adult male patients with thalassemia major: An update for clinicians caring for thalassemia

Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline

Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations from the Lisbon 2018 International Consultation for Sexual Medicine

European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization

Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I

Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline PART II

European Association of Urology Guidelines on Sexual and Reproductive Health-2021 Update: Male Sexual Dysfunction

A review of WHO Laboratory Manual for the Examination and Processing of Human Semen

Current updates on laboratory techniques for the diagnosis of male reproductive failure

Diabetes and Glucose Metabolism in Thalassemia Major: An Update

Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2020

A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm-2020 Executive Summary

Thyroid dysfunction in thalassaemic patients: Ferritin as a prognostic marker and combined iron chelators as an ideal therapy

Raffaella Origa Thyroid Disorders in Homozygous β-Thalassemia: Current Knowledge, Emerging Issues and Open Problems

ETA Guideline: Management of Subclinical Hypothyroidism

Subclinical Hypothyroidism: A Review

Subclinical hypothyroidism: To treat or not to treat?

European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism

Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association

Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement

Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum

European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction

An ICET-A survey on Hypoparathyroidism in Patients with Thalassaemia Major and Intermedia: A preliminary report

Presentation of Hypoparathyroidism: Etiologies and Clinical Features

Management of Hypoparathyroidism: Summary Statement and Guidelines

Diagnosis and treatment of hypoparathyroidism: A position statement from the Brazilian Society of Endocrinology and Metabolism

European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults

Standards of care for hypoparathyroidism in adults: A Canadian and International Consensus

American Thyroid Association Statement on Postoperative Hypoparathyroidism: Diagnosis, Prevention, and Management in Adults. Thyroid

The pituitary-adrenal axis in adult thalassaemic patients

High prevalence of "biochemical" adrenal insufficiency in thalassemics: Is it a matter of different testings or decreased cortisol binding globulin?

The Frequency of Adrenal Insufficiency in Adolescents and Young Adults with Thalassemia Major versus Thalassemia Intermedia in Iran

New Insights and Methods in the Approach to Thalassemia Major: The Lesson from the Case of

Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline

The Icet-A Survey on Current Criteria Used by Clinicians for the Assessment of Central Adrenal Insufficiency in Thalassemia: Analysis of Results and Recommendations

Group 5: Acute adrenal insufficiency in adults and pediatric patients

Group 4: Replacement therapy for adrenal insufficiency

Adrenal insufficiency: Screening methods and confirmation of diagnosis

Growth hormone deficiency in adults with thalassemia: An overview and the I-CET recommendations

Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays

Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline

Growth and Growth hormone-Insulin Like Growth Factor-I (GH-IGF-I) Axis in Chronic Anemias

American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care

Management of the aging beta-thalassemia transfusion-dependent population-The Italian experience

Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: A historical cohort study in Southern Iran

of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors

American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules-2016 Update Appendix

Italian consensus on diagnosis and treatment of differentiated thyroid cancer: Joint statements of six Italian societies

Long-term improvement in cardiac magnetic resonance in β-thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function

Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: The Optimal Care study

Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT)

Thalassaemia International Federation

Current challenges in the management of patients with sickle cell disease-A report of the Italian experience

HNF-1β mutation affects PKD2 and SOCS3 expression causing renal cysts and diabetes in MODY5 kindred

Access to emergency departments for acute events and identification of sickle cell disease in refugees

Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease

Endocrine and metabolic complications in children and adolescents with Sickle Cell Disease: An Italian cohort study

Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis

Therapy Insight: Metabolic and endocrine disorders in sickle cell disease

Endocrine and Bone Complications in β-Thalassemia Intermedia: Current Understanding and Treatment

Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management

Evaluation of endocrine complications in beta-thalassemia intermedia (β-TI): A cross-sectional multicenter study

Question no. 65: How often should screening for hypothyroidism be performed? Recommendation 65.1 It is suggested to repeat screening for hypothyroidism once a year in patients with normal thyroid function, and every six months in patients with non-optimal iron parameters. Recommendation 12.3 In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12. 6 In the case of diagnosis of hypogonadotropic hypogonadism, it is recommended to carry out a pituitary MRI to complete the diagnosis. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.Strength Severe short stature (stature ≤ −2.5 SD); -Stature ≤ −1.5 SD compared to the family target and growth rate (GR) ≤ −2 SD or ≤−1.5 SD after 2 consecutive years; -Stature ≤ −2 SD with GR ≤ −1 SD evaluated at least 6 months apart, or stature reduction of 0.5 SD in one year in children over 2 years old; -If no short stature is present, GR ≤ −2 SD in one year, or ≤−1.5 SD in two consecutive years. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism. In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females. In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.Strength In the case of constitutional growth and puberty delay with the spontaneous beginning of puberty, it is suggested to reassure and remain in watchful waiting, in concert with the patient and his/her parents, with periodic clinical laboratory checks to be carried out every 3-6 months.Strength of Recommendation: Conditioned Panel Agreement: Full Recommendation 13.2 In all patients who do not begin pubertal development, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 13. 3 In the case that pubertal development does not begin, it is recommended to start the therapy no earlier than the chronological age of 14 or the bone age of 12 in males; no earlier than the chronological age of 13 or the bone age of 11 in females.Strength of Recommendation: Strong Panel Agreement: Full Question no. 14: Which is the hormone therapy for puberty delay in males? Recommendation 14.1 In patients with puberty delay, the hormone therapy recommended in males is testosterone enanthate, propionate or cypionate in depot formulation, to be administered every 4 weeks, with an initial dose of 50 mg, for a period of 3-6 months. In patients with height growth disorders, it is recommended to check the optimal control of the therapy for haemoglobinopathy, and to evaluate: -Pretransfusion Hb; -

Hepatic and renal function, electrolytes, total proteins, and protein electrophoresis, physical and chemical examination of urine; - In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5 Boys/girls with a disorder of pubertal development, as previously described, reduced growth rate, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a lack of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have hypogonadotropic hypogonadism.Strength In all patients who did not begin pubertal development, by the age of 13 in females and 14 in males, a short 3-6-month cycle of low-dose hormone therapy (oestrogens in females and testosterone in males) is recommended, followed by a treatment-free period with a clinical laboratory re-evaluation, in order to differentiate between constitutional growth and puberty delay and hypogonadotropic hypogonadism.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.4 Boys/girls with disorders of pubertal development, as previously described, low values of LH, FSH, 17β-estradiol in females, and of total testosterone in males, with a restart of pubertal development after 1-2 cycles of pubertal induction with low-dose hormones, have a constitutional growth and puberty delay.Strength of Recommendation: Strong Panel Agreement: Full Recommendation 12.5